10 notable pharma and biotech venture capital armsMay 23Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Eight biotech companies leading Ohio's innovation frontier in 20248 hours agoJules AdamBy Jules Adammore_vert
Biotech career fairs in the U.S. you don't want to miss4 days agoRoohi Mariam PeterBy Roohi Mariam Petermore_vert
The biggest private biotech investments in May 2024YesterdayWillow Shah-nevilleBy Willow Shah-nevillemore_vert
Covalent biologics: a new class of drugs on the horizon5 days agoRoohi Mariam PeterBy Roohi Mariam Petermore_vert
KRAS Inhibitors: Promising weapons against aggressive cancersMay 22Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Mammalian cell lines: The catalyst for biopharma advancementMay 21Sudha SundaramBy Sudha Sundarammore_vert
Isarna Therapeutics revolutionizes ophthalmology with antisense oligonucleotidesMay 17Jim CornallBy Jim Cornallmore_vert
Five orthobiologics companies leading the way in the fieldMay 16Willow Shah-nevilleBy Willow Shah-nevillemore_vert
The biggest private biotech investments in April 2024May 9Willow Shah-nevilleBy Willow Shah-nevillemore_vert
BTK inhibitors: promising therapies for cancer and autoimmunityMay 9Roohi Mariam PeterBy Roohi Mariam Petermore_vert
The rise of Spain: A key player in global clinical trialsMay 6Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Biologics testing: The right time to move to new standards?Apr 30Ute BoronowskyBy Ute Boronowskymore_vert
Complex innovative designs: tackling rare disease trial challengesApr 23Ute BoronowskyBy Ute Boronowskymore_vert
The biggest private biotech investments in March 2024Apr 22Willow Shah-nevilleBy Willow Shah-nevillemore_vert
5 RNA editing companies you should know aboutApr 19Willow Shah-nevilleBy Willow Shah-nevillemore_vert
8 of the most expensive drugs in biopharma: Unraveling the costliest medicationsApr 25Willow Shah-nevilleBy Willow Shah-nevillemore_vert
WuXi AppTec controversy: A catalyst for national security vigilanceApr 24Jules AdamBy Jules Adammore_vert
Seven groundbreaking mRNA companies to look out forApr 11Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Colossal Biosciences aims to revive the woolly mammoth by 2028Apr 5Jim CornallBy Jim Cornallmore_vert
Small but mighty: The role of small-molecule drugs in disease treatmentApr 17Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Eight biotech companies you should know about in AustriaApr 9Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Does the FDA need to tighten its grip on drug trials in the U.S.?Apr 15Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Are new treatments for multiple sclerosis on the horizon?Mar 27Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Doloromics: Revolutionizing chronic pain treatment with omicsApr 12Jim CornallBy Jim Cornallmore_vert
Are these T cell receptor (TCR) therapy companies on your radar?Apr 1Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Large molecule manufacturing: Challenges and winning strategiesMar 26Alexander BurikBy Alexander Burikmore_vert
Amycretin: Novo Nordisk's new rival to Wegovy in obesity treatmentMar 27Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Advances in Rett syndrome treatment: the rise of gene therapyMar 14Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Biotech scene in France: key findings from France Biotech reportMar 21Jules AdamBy Jules Adammore_vert
Eight CAR-T cell therapy companies you should know aboutMar 21Roohi Mariam PeterBy Roohi Mariam Petermore_vert